These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25534390)

  • 1. Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence from an individual patient data meta-analysis.
    Phi XA; Houssami N; Obdeijn IM; Warner E; Sardanelli F; Leach MO; Riedl CC; Trop I; Tilanus-Linthorst MM; Mandel R; Santoro F; Kwan-Lim G; Helbich TH; de Koning HJ; Van den Heuvel ER; de Bock GH
    J Clin Oncol; 2015 Feb; 33(4):349-56. PubMed ID: 25534390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
    Riedl CC; Luft N; Bernhart C; Weber M; Bernathova M; Tea MK; Rudas M; Singer CF; Helbich TH
    J Clin Oncol; 2015 Apr; 33(10):1128-35. PubMed ID: 25713430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.
    Phi XA; Saadatmand S; De Bock GH; Warner E; Sardanelli F; Leach MO; Riedl CC; Trop I; Hooning MJ; Mandel R; Santoro F; Kwan-Lim G; Helbich TH; Tilanus-Linthorst MM; van den Heuvel ER; Houssami N
    Br J Cancer; 2016 Mar; 114(6):631-7. PubMed ID: 26908327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
    van Zelst JCM; Mus RDM; Woldringh G; Rutten MJCM; Bult P; Vreemann S; de Jong M; Karssemeijer N; Hoogerbrugge N; Mann RM
    Radiology; 2017 Nov; 285(2):376-388. PubMed ID: 28609204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
    Obdeijn IM; Mann RM; Loo CCE; Lobbes M; Voormolen EMC; van Deurzen CHM; de Bock G; ; Hooning MJ
    Breast Cancer Res Treat; 2020 Jun; 181(3):581-588. PubMed ID: 32333294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
    Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
    Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
    Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet?
    Whitaker KD; Sheth D; Olopade OI
    Breast Cancer Res Treat; 2020 Sep; 183(2):243-250. PubMed ID: 32621252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
    Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
    Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
    JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features.
    Gilbert FJ; Warren RM; Kwan-Lim G; Thompson DJ; Eeles RA; Evans DG; Leach MO;
    Radiology; 2009 Aug; 252(2):358-68. PubMed ID: 19703879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI.
    Vreemann S; van Zelst JCM; Schlooz-Vries M; Bult P; Hoogerbrugge N; Karssemeijer N; Gubern-Mérida A; Mann RM
    Breast Cancer Res; 2018 Aug; 20(1):84. PubMed ID: 30075794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in
    Guindalini RSC; Zheng Y; Abe H; Whitaker K; Yoshimatsu TF; Walsh T; Schacht D; Kulkarni K; Sheth D; Verp MS; Bradbury AR; Churpek J; Obeid E; Mueller J; Khramtsova G; Liu F; Raoul A; Cao H; Romero IL; Hong S; Livingston R; Jaskowiak N; Wang X; Debiasi M; Pritchard CC; King MC; Karczmar G; Newstead GM; Huo D; Olopade OI
    Clin Cancer Res; 2019 Mar; 25(6):1786-1794. PubMed ID: 30154229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI breast screening in high-risk women: cancer detection and survival analysis.
    Evans DG; Kesavan N; Lim Y; Gadde S; Hurley E; Massat NJ; Maxwell AJ; Ingham S; Eeles R; Leach MO; ; Howell A; Duffy SW
    Breast Cancer Res Treat; 2014 Jun; 145(3):663-72. PubMed ID: 24687378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.
    Lowry KP; Lee JM; Kong CY; McMahon PM; Gilmore ME; Cott Chubiz JE; Pisano ED; Gatsonis C; Ryan PD; Ozanne EM; Gazelle GS
    Cancer; 2012 Apr; 118(8):2021-30. PubMed ID: 21935911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
    Griebsch I; Brown J; Boggis C; Dixon A; Dixon M; Easton D; Eeles R; Evans DG; Gilbert FJ; Hawnaur J; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Potterton J; Thompson D; Turnbull LW; Walker LG; Warren R; Leach MO;
    Br J Cancer; 2006 Oct; 95(7):801-10. PubMed ID: 17016484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
    Liljegren A; von Wachenfeldt A; Azavedo E; Eloranta S; Grundström H; Ståhlbom AK; Sundbom A; Sundén P; Svane G; Ulitzsch D; Arver B
    Breast Cancer Res Treat; 2018 Apr; 168(3):655-666. PubMed ID: 29318406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
    Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
    Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.